KEYNOTE-667: PHASE 2 STUDY OF PEMBROLIZUMAB IN CHILDREN AND YOUNG ADULTS WITH NEWLY DIAGNOSED CLASSICAL HODGKIN LYMPHOMA WITH SLOW EARLY RESPONSE TO FRONTLINE CHEMOTHERAPY - Research portal of Justus Liebig University Giessen:

Meeting Abstract

KEYNOTE-667: PHASE 2 STUDY OF PEMBROLIZUMAB IN CHILDREN AND YOUNG ADULTS WITH NEWLY DIAGNOSED CLASSICAL HODGKIN LYMPHOMA WITH SLOW EARLY RESPONSE TO FRONTLINE CHEMOTHERAPY

Authors list: Vinti, Luciana; Daw, Stephen; Alvarez, Constantino Sabado; Fagioli, Franca; Beishuizen, Auke; Michel, Gerard; Moleti, Maria Luisa; Cepelova, Michaela; Thorwarth, Anne; Rigaud, Charlotte; De Sabando, Diego Plaza Lopez; Parker, Judith Landman; Zhu, Ying; Pillai, Pallavi; Nahar, Akash; Mauz-Koerholz, Christine

Publication year: 2022

Journal: Pediatric Blood & Cancer

Volume number: 69

ISSN: 1545-5009

eISSN: 1545-5017

Publisher: Wiley

Citation Styles

Harvard Citation style: Vinti, L., Daw, S., Alvarez, C., Fagioli, F., Beishuizen, A., Michel, G., et al. (2022) KEYNOTE-667: PHASE 2 STUDY OF PEMBROLIZUMAB IN CHILDREN AND YOUNG ADULTS WITH NEWLY DIAGNOSED CLASSICAL HODGKIN LYMPHOMA WITH SLOW EARLY RESPONSE TO FRONTLINE CHEMOTHERAPY, Pediatric Blood & Cancer, 69

APA Citation style: Vinti, L., Daw, S., Alvarez, C., Fagioli, F., Beishuizen, A., Michel, G., Moleti, M., Cepelova, M., Thorwarth, A., Rigaud, C., De Sabando, D., Parker, J., Zhu, Y., Pillai, P., Nahar, A., & Mauz-Koerholz, C. (2022). KEYNOTE-667: PHASE 2 STUDY OF PEMBROLIZUMAB IN CHILDREN AND YOUNG ADULTS WITH NEWLY DIAGNOSED CLASSICAL HODGKIN LYMPHOMA WITH SLOW EARLY RESPONSE TO FRONTLINE CHEMOTHERAPY. Pediatric Blood & Cancer. 69.